MetaADEDB 2.0 @ LMMD
Hyoscyamine
(RKUNBYITZUJHSG-VFSICIBPSA-N)
Structure
SMILES
OC[C@H](c1ccccc1)C(=O)OC1C[C@@H]2CC[C@H](C1)N2C
Type(s)
Approved
ATC code(s)
A03BA03; A03CB31
Molecular Formula:
C17H23NO3
Molecular Weight:
289.369
Log P:
1.8688
Hydrogen Bond Acceptor:
4
Hydrogen Bond Donor:
1
TPSA:
49.77
CAS Number(s):
101-31-5; 5908-99-6; 5934-50-9
Synonym(s)
1.
Hyoscyamine
2.
Atropine Sulfate, 3(S)-endo-Isomer
3.
Hyoscyamine Sulfate
4.
Anaspaz
5.
Atropine, 3(S)-endo-Isomer
6.
Cytospaz
7.
Hyoscyamine Hydrobromide
8.
Hyoscyamine Hydrochloride
9.
Hyoscyamine Sulfate Anhydrous
External Link(s)
MeSHD064692
PubChem Compound154417
ChEBI17486
92712
CHEMBLCHEMBL1234973
CHEMBL2449003
CHEMBL1331216
DrugBankDB00424
DrugCentral1402
KEGGcpd:C02046
dr:D00147
Therapeutic Target DatabaseD0NZ3Q
ZINC56
100009280
100068360
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1DizzinessFAERS: 6US FAERS
2Product use issueFAERS: 6US FAERS
3OverdoseFAERS: 4US FAERS
4Product quality issueFAERS: 4US FAERS
5HeadacheFAERS: 3US FAERS
6MalaiseFAERS: 3US FAERS
7Medication ErrorFAERS: 3US FAERS
8Product solubility abnormalFAERS: 3US FAERS
9Product substitution issueFAERS: 3US FAERS
10Adverse eventFAERS: 2US FAERS
11AnxietyFAERS: 2US FAERS
12DysgeusiaFAERS: 2US FAERS
13DysuriaFAERS: 2US FAERS
14FlatulenceFAERS: 2US FAERS
15Mental status changesFAERS: 2US FAERS
16NauseaFAERS: 2US FAERS
17Pharmaceutical product complaintFAERS: 2US FAERS
18SomnolenceFAERS: 2US FAERS
19AbasiaFAERS: 1US FAERS
20Abdominal PainFAERS: 1US FAERS
21AgitationFAERS: 1US FAERS
22AmnesiaFAERS: 1US FAERS
23AngerFAERS: 1US FAERS
24Buccal mucosal rougheningFAERS: 1US FAERS
25Chest PainFAERS: 1US FAERS
26Chest discomfortFAERS: 1US FAERS
27Disease recurrenceFAERS: 1US FAERS
28DisorientationFAERS: 1US FAERS
29Drug dispensing errorFAERS: 1US FAERS
30Drug effect delayedFAERS: 1US FAERS
31Drug ineffectiveFAERS: 1US FAERS
32Drug prescribing errorFAERS: 1US FAERS
33Dry skinFAERS: 1US FAERS
34DysarthriaFAERS: 1US FAERS
35Feeling abnormalFAERS: 1US FAERS
36HypersensitivityFAERS: 1US FAERS
37Impaired work abilityFAERS: 1US FAERS
38IncoherentFAERS: 1US FAERS
39Intercepted drug dispensing errorFAERS: 1US FAERS
40Malabsorption from administration siteFAERS: 1US FAERS
41Mental impairmentFAERS: 1US FAERS
42Middle insomniaFAERS: 1US FAERS
43Musculoskeletal PainFAERS: 1US FAERS
44PainFAERS: 1US FAERS
45PalpitationsFAERS: 1US FAERS
46Product label confusionFAERS: 1US FAERS
47Product physical issueFAERS: 1US FAERS
48Product taste abnormalFAERS: 1US FAERS
49Restless Legs SyndromeFAERS: 1US FAERS
50RestlessnessFAERS: 1US FAERS
51Sleep disorder due to general medical condition, insomnia typeFAERS: 1US FAERS
52Slow speechFAERS: 1US FAERS
53StressFAERS: 1US FAERS
54Suppressed lactationFAERS: 1US FAERS
55TachycardiaFAERS: 1US FAERS
56ThirstFAERS: 1US FAERS
57Throat irritationFAERS: 1US FAERS
58TremorFAERS: 1US FAERS
59Urinary RetentionFAERS: 1US FAERS
60VertigoFAERS: 1US FAERS
61VomitingFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.